$-0.39
(Market cap
$39 Mln
Revenue (TTM)
$4 Mln
P/E Ratio
--
P/B Ratio
0.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-19 Mln
-
ROE
-0.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.9
-
Debt to Equity
0
-
Book Value
$0.4
-
EPS
$-0.5
-
Face value
--
-
Shares outstanding
147,372,131
10 Years Aggregate
CFO
A$-159.49 Mln
EBITDA
A$-235.03 Mln
Net Profit
A$-261.37 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Immutep - ADR
| 70.6 | 1,181.5 | 1,149.7 | 183.7 | 36.5 | 3.9 | 5.2 |
|
BSE Sensex
| -14.1 | -5.4 | -5.6 | -9.5 | 3.2 | 3.9 | 9.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Immutep - ADR
| 31.8 | -9.5 | 37.1 | -46.6 | 4.5 | 75.4 | -2.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Immutep - ADR
|
4.9 | 38.8 | 14.2 | -77.6 | -1,706.4 | -75.6 | -- | 0.9 |
| 3.5 | 66.8 | 0.0 | -22.9 | -581.6 | -53.8 | -- | 2.3 |
Shareholding Pattern
View DetailsAbout Immutep - ADR
Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or... IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (1L HNSCC); an investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in patients with early-stage HR+/HER2-negative breast cancer; and EFTISARC-NEO, which is in a Phase II clinical trial for the treatment of soft tissue sarcoma. In addition, the company develops INSIGHT-003, which is in a Phase I trial for 1L non squamous non-small cell lung cancer (NSCLC); EOC 202, which has completed a Phase I trial for metastatic breast cancer; IMP761, an agonist LAG-3 antibody in a Phase I trial; IMP731, a LAG-3 depleting antibody that has completed a Phase II trial for ulcerative colitis and a Phase I trial for psoriasis; and ieramilimab/LAG525/IMP701, which are anti-LAG-3 antagonist antibodies. It has collaborations with Merck & Co., Inc., Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest, the Maria Sklodowska-Curie National Research Institute of Oncology, EOC Pharma, Dr Reddy's Laboratories, Monash University, and George Washington University. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia. Read more
-
CEO, MD, CFO, Chief Business Officer & Executive Director
Mr. Marc Voigt
-
CEO, MD, CFO, Chief Business Officer & Executive Director
Mr. Marc Voigt
-
Headquarters
Sydney, NSW
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Immutep - ADR
What is the current share price of Immutep Limited - ADR Today?
The share price of Immutep Limited - ADR is $4.88 (NASDAQ) as of 28-Sep-2026 16:00 EDT. Immutep Limited - ADR has given a return of 36.47% in the last 3 years.
What is the current PB & PE ratio of Immutep Limited - ADR?
Since, TTM earnings of Immutep Limited - ADR is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2026 |
-0.79 |
1.00 |
2025 |
-3.89 |
1.67 |
2024 |
-5.72 |
1.29 |
2023 |
-4.74 |
1.39 |
2022 |
-5.46 |
1.87 |
What is the 52 Week High and Low of Immutep Limited - ADR?
The 52-week high and low of Immutep Limited - ADR are Rs 70.60 and Rs 4.67 as of 29-Sep-2026.
What is the market cap of Immutep Limited - ADR?
Immutep Limited - ADR has a market capitalisation of $ 39 Mln as on 25-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Immutep Limited - ADR?
Before investing in Immutep Limited - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.